Last month, Rep Khanna (D,CA) introduced HR 10569, the Protecting Biotechnology and Biomanufacturing as Critical Infrastructure Act. The bill would amend 6 USC 652 to require CISA to treat biotechnology and biomanufacturing as critical infrastructure even though it does not have a designated Sector Specific Agency designation. No new funding is authorized by this bill.
According to a press release from the office of Rep Peters (D,CA), a cosponsor of this bill:
“America’s leadership in the sector is a strategic advantage we cannot take for granted. As technology advances and our adversaries grow more capable, American national security, public health, and competitiveness will continue to face more serious threats. Our legislation will strengthen America’s biotech ecosystem against cyber threats, supply chain disruptions, and other vulnerabilities. To maintain our leadership in biotechnology, we need to make sure that the United States remains a safe place to innovate.”
Moving Forward
Neither Khanna, nor his two cosponsors, are members of the House Homeland Security Committee to which this bill was assigned for consideration. This means that there is little chance of the bill being considered by that Committee. I would not expect that Committee to consider the bill because of its reliance on the outdated ‘Sector-Specific Agency’ terminology.
For more information on the provisions of this bill, see my article at CFSN Detailed Analysis - https://patrickcoyle.substack.com/p/hr-10569-introduced-cisa-and-biosecurity - subscriptions required.